Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731355 | 0.80 | TSHR (0.46) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL8879203 | 0.79 | — | — | |
| SCHEMBL2356791 | 0.68 | TSHR (0.48) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL2491743 | 0.68 | TSHR (0.48) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL11313184 | 0.68 | CA12 (0.35) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL8346052 | 0.66 | — | — | |
| SCHEMBL491379 | 0.66 | CA12 (0.44) | CA12CA1CA2CA9TSHR | |
| SCHEMBL25291415 | 0.65 | TSHR (0.43) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL4904063 | 0.65 | TSHR (0.43) | CA12CA1CA2CA9HMGCR | |
| SCHEMBL10387762 | 0.65 | TP53 (0.46) | CA12CA1CA2CA9HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| EP-2455059-A1 | Polymerisable compound having improved hardening depth | Ivoclar Vivadent AG (LI) | 2012-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | NR4A2, NR2C2, NOS2 | CA12 736/4885CA1 754/4885CA2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.